{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:32:23Z","timestamp":1792017143622,"version":"4.4.0"},"reference-count":109,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2022,12,2]]},"DOI":"10.1080\/14712598.2022.2132143","type":"journal-article","created":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T22:47:50Z","timestamp":1665874070000},"page":"1489-1502","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":26,"title":["Anti-IL 23 biologics for the treatment of plaque psoriasis"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3902-7791","authenticated-orcid":false,"given":"Alan","family":"Vu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caden","family":"Ulschmid","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.064"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.036"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.026"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.04.012"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.906"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.05.017"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2021.01.004"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S290309"},{"key":"cit0014","unstructured":"Enbrel (etanercept) [package insert]. Thousand Oaks CA: Immunex Corporation; 2021."},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.11.1088"},{"key":"cit0016","unstructured":"Remicade (infliximab) [package insert]. Horsham PA: Janssen Biotech, Inc. 2021."},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.07.017"},{"key":"cit0018","unstructured":"Humira (adalimumab) [package insert]. North Chicago IL: AbbVie Inc. 2021."},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"cit0020","unstructured":"Cimzia (certolizumab pegol) [package insert]. Smyrna GA: UCB, Inc. 2019."},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.013"},{"key":"cit0022","unstructured":"Cosentyx (secukinumab) [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; 2021."},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"cit0024","unstructured":"Taltz (ixekizumab) [package insert]. Indianapolis IN: Eli Lilly and Company; 2021."},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"cit0026","unstructured":"Siliq (brodalumab) [package insert]. Grand Duchy of Luxembourg, L-1931. Luxembourg: Valeant Pharmaceuticals Luxembourg S.\u00e0.r.l. 2017."},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2020.05.008"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800013"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.11.005"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)00070-4"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.11.5699"},{"key":"cit0033","unstructured":"Stelara (ustekinumab) [package insert]. Horsham PA: Janssen Biotech, Inc. 2020."},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"cit0036","unstructured":"Stelara (ustekinumab) European public assessment report (EPAR). European Medicines Agency; 2009 [cited 2020 Apr 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stelara"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.002"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19018"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12046"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13469"},{"issue":"7","key":"cit0041","first-page":"706","volume":"14","author":"Papp K","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"cit0042","unstructured":"Tremfya (guselkumab) [package insert]. Horsham PA: Janssen Biotech, Inc. 2020."},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"cit0045","unstructured":"Tremfya (guselkumab) European public assessment report (EPAR). European Medicines Agency; 2017 [cited 2022 Mar 9]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tremfya"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15750"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.01.047"},{"key":"cit0049","unstructured":"A study of guselkumab subcutaneous therapy in participants with moderately to severely active crohn\u2019s disease (GRAVITI). U.S. National Institutes of Health; 2022 [cited 2022 Jun 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05197049"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1938538"},{"key":"cit0051","unstructured":"Guselkumab in the treatment of pityriasis rubra pilaris (PRP). U.S. National Institutes of Health; 2019 [cited 2022 Apr 12]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03975153"},{"key":"cit0052","unstructured":"Guselkumab for hidradenitis suppurativa, a mode of action study (HiGUS). U.S. National Institutes of Health; 2019 [cited 2019 Aug 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04061395"},{"key":"cit0053","unstructured":"A study of guselkumab in participants with familial adenomatous polyposis. U.S. National Institutes of Health; 2018 [cited 2022 Jul 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03649971"},{"key":"cit0054","unstructured":"A study to evaluate guselkumab for the treatment of participants with new-onset or relapsing giant cell arteritis (THEIA). U.S. National Institutes of Health; 2020 [cited 2022 Sep 9]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04633447"},{"key":"cit0055","unstructured":"A study of guselkumab therapy in participants with moderately to severely active ulcerative colitis (ASTRO). U.S. National Institutes of Health; 2022 [cited 2022 Sept 6]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05528510"},{"key":"cit0056","unstructured":"A study of guselkumab in participants with systemic sclerosis. U.S. National Institutes of Health; 2020 [cited 2022 Jul 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04683029"},{"key":"cit0057","unstructured":"An efficacy and safety study of CNTO1959 (Guselkumab) in the treatment of participants with generalized pustular psoriasis or erythrodermic Psoriasis. U.S. National Institutes of Health; 2015 [cited 2019 Oct 24]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02343744"},{"key":"cit0058","unstructured":"A study of guselkumab in participants with active lupus nephritis (ORCHID-LN). U.S. National Institutes of Health; 2020 [cited 2022 Sep 9]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04376827"},{"key":"cit0059","unstructured":"Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease. U.S. National Institutes of Health; 2021 [cited 2021 May 5]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04736966"},{"key":"cit0060","unstructured":"A study to evaluate the efficacy, safety, and pharmacokinetics of subcutaneously administered guselkumab for the treatment of chronic plaque psoriasis in pediatric participants (PROTOSTAR). U.S. National Institutes of Health; 2018 [cited 2022 Sep 9]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03451851"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00555-7"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.11.004"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"cit0064","unstructured":"Ilumya (tildrakizumab-asmn) [package insert]. Whitehouse Station NJ: Merck & Co., Inc. 2018."},{"key":"cit0065","unstructured":"Ilumetri (tildrakizumab) European public assessment report (EPAR). European Medicines Agency; 2018 [cited 2022 May 13]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ilumetri"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219014"},{"key":"cit0067","unstructured":"The effects of tildrakizumab in treatment of bullous pemphigoid. U.S. National Institutes of Health; 2020 [cited 2020 Jul 10]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04465292"},{"key":"cit0068","unstructured":"Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo (TILDVIT-1227). U.S. National Institutes of Health; 2021 [cited 2022 Apr 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04971200"},{"key":"cit0069","unstructured":"Tildrakizumab for prevention of acute graft-versus-host disease. U.S. National Institutes of Health; 2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04112810"},{"key":"cit0070","unstructured":"Efficacy and Safety Study of SUNPG1622. U.S. National Institutes of Health; 2016 [cited 2021 Nov 1]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02980705"},{"key":"cit0071","unstructured":"A study of tildrakizumab in pediatric subjects with chronic plaque psoriasis. U.S. National Institutes of Health; 2019 [cited 2022 Aug 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03997786"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19866"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16724"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18232"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00660-3"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30952-3"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0723"},{"key":"cit0079","unstructured":"Skyrizi (risankizumab-rzaa) [package insert]. North Chicago IL: AbbVie Inc. 2022."},{"key":"cit0080","unstructured":"Skyrizi (risankizumab) European public assessment report (EPAR). European Medicines Agency; 2019 [cited 2022 Apr 1]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/skyrizi"},{"key":"cit0081","unstructured":"A study of subcutaneous risankizumab injection for pediatric participants with moderate to severe plaque psoriasis to assess change in disease Symptoms. U.S. National Institutes of Health; 2020 [cited 2022 May 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04435600?"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030880"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30233-4"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221019"},{"key":"cit0085","unstructured":"A global study comparing risankizumab to placebo in adult participants with moderate to severe hidradenitis suppurativa (DETERMINED 1). U.S. National Institutes of Health; 2018 [cited 2022 Jan 5]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03926169"},{"key":"cit0086","unstructured":"Multicenter A, Randomized D-B, Placebo controlled induction study to evaluate the efficacy and safety of risankizumab in subjects with moderately to severely active ulcerative colitis. U.S. National Institutes of Health; 2018 [cited 2022 Jun 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03398148"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14941"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18010"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20595"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20568"},{"key":"cit0091","unstructured":"A study to assess the efficacy of risankizumab compared to FUMADERM\u00ae in subjects with moderate to severe plaque psoriasis who are na\u00efve to and candidates for systemic therapy. U.S. National Institutes of Health; 2017 [cited 2019 Sep 13]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03255382"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18232"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12214"},{"key":"cit0094","unstructured":"Bimzelx (bimekizumab) Eurpoean public assessment report (EPAR). European Medicines Agency; 2021 [cited 2022 May 17]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bimzelx"},{"key":"cit0095","unstructured":"A study of mirikizumab (LY3074828) in participants with active Crohn\u2019s disease (SERENITY). U.S. National Institutes of Health; 2016 [cited 2022 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02891226"},{"key":"cit0096","unstructured":"An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1). U.S. National Institutes of Health; 2018 [cited 2022 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03518086"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213328"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1002\/art.40728"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002410"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045625"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174170"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00649-y"},{"key":"cit0104","volume-title":"30th EADV Congress","author":"Warren RB","year":"2021"},{"key":"cit0105","unstructured":"Effectiveness and safety of BMS-986165 compared to placebo and active comparator in participants with psoriasis (POETYK-PSO-1). U.S. National Institutes of Health; 2018 [cited 2021 Sept 5]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03624127"},{"key":"cit0106","unstructured":"An investigational study to evaluate experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate-to-severe plaque psoriasis (POETYK-PSO-2): U.S. National Institutes of Health; 2018 [cited 2021 Dec 3]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03611751"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"cit0108","volume-title":"30th EADV Congress","author":"Tha\u00e7i D","year":"2021"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664"}],"updated-by":[{"DOI":"10.1080\/14712598.2022.2151761","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000}}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2022.2132143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T10:38:24Z","timestamp":1674643104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2022.2132143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":109,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,2]]}},"alternative-id":["10.1080\/14712598.2022.2132143"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2022.2132143","relation":{"correction":[{"id-type":"doi","id":"10.1080\/14712598.2022.2151761","asserted-by":"object"}]},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-07-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}